World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
43
Citations
7351
World Ranking
5251
National Ranking
2001

Best Publications

  • Platensimycin is a selective FabF inhibitor with potent antibiotic properties

    Jun Wang;Stephen M. Soisson;Katherine Young;Wesley Shoop;Wesley Shoop

  • Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.

    Jun Wang;Srinivas Kodali;Sang Ho Lee;Andrew Galgoci

  • Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

    M.A. Pfaller;D.J. Diekema;D. Andes;M.C. Arendrup

  • Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.

    Johan A Maertens;Galia Rahav;Galia Rahav;Dong-Gun Lee;Alfredo Ponce-de-León

  • Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

    Frank C. Odds;Mary Motyl;Roberto Andrade;Jacques Bille

  • Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome

    Unknown

  • Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

    M. A. Pfaller;D. J. Diekema;M. A. Ghannoum;J. H. Rex

  • Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

    Michael A. Pfaller;David Andes;Maiken C. Arendrup;Daniel J. Diekema

  • Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene.

    Yasufumi Matsumura;Johann D.D. Pitout;Ryota Gomi;Tomonari Matsuda

  • Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

    A. L. Colombo;J. Perfect;M. DiNubile;K. Bartizal

  • In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

    Elizabeth B. Hirsch;Kimberly R. Ledesma;Kai Tai Chang;Michael S. Schwartz

  • In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

    Sibylle H. Lob;Meredith A. Hackel;Krystyna M. Kazmierczak;Katherine Young

  • Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008-2014.

    Gisele Peirano;Yasufumi Matsumura;Mark D. Adams;Patricia Bradford

  • Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates

    Cristina Jiménez-Ortigosa;Padmaja Paderu;Mary R. Motyl;David S. Perlin

  • In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested Against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods

    Michael A. Pfaller;Shawn A. Messer;Mary R. Motyl;Ronald N. Jones

  • Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy

    M. J. DiNubile;I. Friedland;C. Y. Chan;M. R. Motyl

  • Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)

    Michael A Pfaller;Shawn A Messer;Mary R Motyl;Ronald N Jones

  • In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

    Katherine Young;Ronald E. Painter;Susan L. Raghoobar;Nichelle N. Hairston

  • Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli.

    N. Stoesser;A.E. Sheppard;G. Peirano;L.W. Anson

  • In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014

    James A. Karlowsky;Sibylle H. Lob;Krystyna M. Kazmierczak;Robert E. Badal

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Recently Published Articles